Compare SHASUN PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA PANACEA BIOTECH SHASUN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 123.9 12.6 983.1% View Chart
P/BV x 8.5 3.0 281.7% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
PANACEA BIOTECH
Mar-18
SHASUN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs94364 25.9%   
Low Rs46129 35.3%   
Sales per share (Unadj.) Rs214.296.8 221.3%  
Earnings per share (Unadj.) Rs5.3-12.4 -43.0%  
Cash flow per share (Unadj.) Rs15.8-2.9 -554.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.350.4 105.8%  
Shares outstanding (eoy) m56.6261.25 92.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.5 12.8%   
Avg P/E ratio x13.1-19.9 -65.9%  
P/CF ratio (eoy) x4.4-86.4 -5.1%  
Price / Book Value ratio x1.34.9 26.8%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95815,101 26.2%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2,1641,516 142.7%   
Avg. sales/employee Rs ThNM2,401.9-  
Avg. wages/employee Rs ThNM614.2-  
Avg. net profit/employee Rs ThNM-307.9-  
INCOME DATA
Net Sales Rs m12,1275,928 204.6%  
Other income Rs m22982 278.7%   
Total revenues Rs m12,3566,010 205.6%   
Gross profit Rs m1,009845 119.4%  
Depreciation Rs m594585 101.4%   
Interest Rs m4151,006 41.3%   
Profit before tax Rs m230-664 -34.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 -14.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-7399 -73.8%   
Profit after tax Rs m302-760 -39.8%  
Gross profit margin %8.314.3 58.4%  
Effective tax rate %-31.7-14.9 213.0%   
Net profit margin %2.5-12.8 -19.4%  
BALANCE SHEET DATA
Current assets Rs m6,8845,603 122.9%   
Current liabilities Rs m8,4566,910 122.4%   
Net working cap to sales %-13.0-22.0 58.8%  
Current ratio x0.80.8 100.4%  
Inventory Days Days62206 29.9%  
Debtors Days Days10884 128.4%  
Net fixed assets Rs m4,9709,941 50.0%   
Share capital Rs m11361 184.8%   
"Free" reserves Rs m2,8753,026 95.0%   
Net worth Rs m3,0203,087 97.8%   
Long term debt Rs m1,8175,707 31.8%   
Total assets Rs m13,34716,076 83.0%  
Interest coverage x1.60.3 456.4%   
Debt to equity ratio x0.61.8 32.5%  
Sales to assets ratio x0.90.4 246.4%   
Return on assets %5.41.5 351.4%  
Return on equity %10.0-24.6 -40.6%  
Return on capital %13.33.9 340.2%  
Exports to sales %46.424.0 192.9%   
Imports to sales %14.217.5 81.2%   
Exports (fob) Rs m5,6221,424 394.7%   
Imports (cif) Rs m1,7281,040 166.2%   
Fx inflow Rs m5,8431,600 365.2%   
Fx outflow Rs m2,1731,131 192.1%   
Net fx Rs m3,669469 783.1%   
CASH FLOW
From Operations Rs m3981,180 33.7%  
From Investments Rs m-1,635553 -295.7%  
From Financial Activity Rs m1,309-1,644 -79.6%  
Net Cashflow Rs m7190 79.4%  

Share Holding

Indian Promoters % 39.2 74.5 52.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.6 600.0%  
FIIs % 17.6 1.3 1,353.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 23.6 167.8%  
Shareholders   20,750 10,259 202.3%  
Pledged promoter(s) holding % 12.3 35.1 35.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  ORCHID PHARMA LTD  PIRAMAL ENTERPRISES  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS